Biotech News

iSpecimen to Report Fourth Quarter and Full Year 2022 Results on March 14, 2023

iSpecimen (ISPC)iSpecimen2026-06-25 13:46 ESTEarnings

LEXINGTON, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=_5qPVwMaTX8Dk3jZ53fZhNXTqRvDJqZWJeI843HZjIi7NgU9poIlRnkCNVRhnTb76vOKzrMzABLoAZaWHZclz9hDI2rbMhrCN9B5Jafv1LvOEy88HsFxswI_PGJMni1awBSpKcWqrUT8GM4gw6l7bRNcGmcnUibw8mP61r3K6kyyI0ZnjCqFY3eTpWokJ6eEjgmPiEhtiVZKpxsXDbqlXSI4TMXwXWuBNzU3otN8-Jw="...

Open original release

Related news

iSpecimen

iSpecimen is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

Stock data

Close
Market cap
Exchange
NASDAQ
Sector
Biotechnology
Location
United States